Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Explore credit cards that provide flexible redemption options. Redeem your rewards in the way that suits you best.
24,275 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
EWJ has fallen 9% in the past 30 days while Japan’s economy rides on fragile oil supply lines. The shift tests the op...
Ethereum climbs as global tensions weigh on markets, outpacing Bitcoin. ETH rises toward $2,300 as the ETH/BTC ratio ...
Former BitMEX chief Arthur Hayes reportedly acquired a tranche of ETHFI ahead of Upbit's listing, sparking a price sp...
Ripple accelerates its global push as it secures licenses and partnerships while the XRP ETF narrative gains traction...
A new AI compute niche is gaining attention as investors search for growth beyond mega-cap tech. This article outline...
Li Lu’s Himalaya Capital is famous for a bold, value-driven stance and a striking concentration in just a few bets. T...
Freshworks unveils a $400 million share repurchase as it shifts to AI-based pricing, prompting investor debate over w...
Elon Musk announced a Texas-based Terafab chip initiative, a joint venture between TESLA and SPACE X, to build advanc...
The Supreme Court declined to review a high-profile press freedom dispute stemming from a 2017 Texas arrest. The move...
Analysts see Elon Musk's Terafab strategy as a potential catalyst for chip-equipment makers and select chip stocks, b...
JPMorgan's revised target to $134 underscores a brighter backdrop for Bunge as the Viterra deal closes and 2026 biofu...